10 assets in Immunoproliferative Disorder

Therapeutic assets addressing Immunoproliferative Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ibrutinib Immunoproliferative Disorder	Oncternal Therapeutics, Inc	P3	B (60)
Zilovertamab Immunoproliferative Disorder	Oncternal Therapeutics, Inc	P3	B (60)
Atlcar.Cd30.Ccr4 Cells Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Bendamustine Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Cyclophosphamide Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Fludarabine Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
ic9-car19 t cells Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Kln-1010 Immunoproliferative Disorder	Kelonia Therapeutics, Inc.	P1	CC (43)
Oricar-017 Immunoproliferative Disorder	OriCell Therapeutics Co., Ltd.	P1	CC (43)
Rimiducid Immunoproliferative Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)